We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
313 hedge funds and large institutions have $8.17B invested in Royalty Pharma in 2023 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 138 increasing their positions, 114 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
244% more call options, than puts
Call options by funds: $40.5M | Put options by funds: $11.8M
21% more repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 114
4% less funds holding
Funds holding: 326 → 313 (-13)
4.6% less ownership
Funds ownership: 71.36% → 66.76% (-4.6%)
12% less capital invested
Capital invested by funds: $9.32B → $8.17B (-$1.16B)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
26% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 47
Holders
313
Holders Change
-13
Holders Change %
-3.99%
% of All Funds
4.97%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.1%
New
35
Increased
138
Reduced
114
Closed
47
Calls
$40.5M
Puts
$11.8M
Net Calls
+$28.7M
Net Calls Change
+$12.1M
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$35.3M |
| 2 |
Two Sigma Investments
New York
|
+$31.9M |
| 3 |
Two Sigma Advisers
New York
|
+$31.2M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$31.1M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
+$27.6M |
